CAM
FOLD

Close Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Close Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9K Hold
600
– – ﹤0.01% 230
2025
Q4 		$9K Hold
600
– – ﹤0.01% 231
2025
Q3 		$5K Hold
600
– – ﹤0.01% 245
2025
Q2 		$3K Hold
600
– – ﹤0.01% 236
2025
Q1 		$5K Hold
600
– – ﹤0.01% 229
2024
Q4 		$6K Hold
600
– – ﹤0.01% 221
2024
Q3 		$6K Hold
600
– – ﹤0.01% 232
2024
Q2 		$6K Hold
600
– – ﹤0.01% 233
2024
Q1 		$7K Hold
600
– – ﹤0.01% 230
2023
Q4 		$9K Hold
600
– – ﹤0.01% 212
2023
Q3 		$7K Buy
+600
New +$7.74K ﹤0.01% 211

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Close Asset Management's FOLD Position: Q1 2026 in Review

Close Asset Management held its Amicus Therapeutics (FOLD) position steady in Q1 2026 at 600 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #230.

Close Asset Management first reported a position in FOLD in Q3 2023 and has held it in 11 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Close Asset Management held 600 shares of Amicus Therapeutics worth $9K as of Q1 2026.
  • Close Asset Management left its Amicus Therapeutics share count unchanged in Q1 2026.
  • Amicus Therapeutics made up ﹤0.01% of Close Asset Management's portfolio in Q1 2026, its #230 holding.
  • Close Asset Management first reported a position in Amicus Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Close Asset Management's 13F filing for Q1 2026, filed 12 May 2026.